Skip navigation
March 5, 2018

Natera's Genetic Tests Now Fully Integrated into Yale New Haven Health's Epic EMR System

SAN CARLOS, Calif., March 5, 2018 /PRNewswire/ — Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Yale New Haven Health has fully integrated the company’s Panorama® non-invasive prenatal test (NIPT) and Horizon™ carrier screening test into its Epic electronic medical record (EMR) platform, making it easier for physicians to order and receive prenatal genetic testing information.

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

According to Matthew Rabinowitz, Ph.D., Natera’s CEO, this represents another integration for the company’s genetic screening products. "We are pleased to integrate with Yale New Haven Health’s Epic EMR system, making Natera’s tests and patient results readily available to providers throughout its health system," Rabinowitz said. "We have integrated with many of our customers and continue to partner with healthcare systems across the U.S. to help simplify the genetic testing process for providers and improve access to important information about the genetic health of patients and their babies."

Yale New Haven Health, the largest healthcare system in Connecticut, recently adopted Epic’s Stage 7 EMR platform to help connect its expanding health system. The platform allows fully integrated access to patient records and vital information from any location within the health system.

The platform incorporates Natera’s Panorama® NIPT and Horizon™ carrier screening test. Panorama reveals a baby’s risk for genetic disorders as early as nine weeks’ gestation and is the first NIPT that screens for zygosity in twin pregnancies, enabling women to learn more about their pregnancies through a simple blood draw from the mother, posing no risk to the babies. Horizon screens prospective parents’ risk for carrying one or more genetic conditions that can be passed on to their child.

About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.

About Yale New Haven Health
Yale New Haven Health (YNHHS), the largest and most comprehensive healthcare system in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals—Bridgeport, Greenwich, Lawrence + Memorial, Westerly, and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a nonprofit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine. For more information, visit

Forward Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our ability to successfully increase demand for and grow revenues for our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and

Investor Relations
Mike Brophy, CFO, Natera, Inc., 650-249-9091 x 1471, 
Barbara Sullivan, Sullivan & Associates, 714-374-6174,


SOURCE Natera, Inc.

icon-angle icon-bars icon-times